The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Warren, H. S.
Right arrow Articles by Parish, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warren, H. S.
Right arrow Articles by Parish, C. R.

The Journal of Immunology, Vol 156, Issue 8 2866-2873, Copyright © 1996 by American Association of Immunologists


ARTICLES

A carbohydrate structure associated with CD15 (Lewis x) on myeloid cells is a novel ligand for human CD2

HS Warren, JG Altin, JC Waldron, BF Kinnear and CR Parish
Cancer Research Unit, Woden Valley Hospital, Australia.

The T cell and NK cell adhesion molecule CD2 interacts with different ligands, viz, CD58, CD48, and CD59. Using a fluorescent multimeric construct of rCD2, we previously identified an additional CD2 ligand (CD2L) on the erythroleukemic cell line K562. CD2L bound to a different region of CD2 than known ligands and was N-glycosylation dependent. In this study we show that mAbs specific for the carbohydrate Ag Lewis x (CD15, Gal-beta 1-4 GlcNAc alpha 1-3Fuc) inhibit multimeric rCD2 binding to CD2L. CD2L is restricted in expression to myeloid cells, where it is co-expressed with CD58 on monocytes and is the dominant, if not sole, CD2 ligand on neutrophils. Sugar specificity studies show that CD2L is not CD15. Thus, whereas soluble Lewis x inhibits binding of CD15 mAb to K562 and neutrophils, binding of multimeric rCD2 is unaffected. Furthermore, multimeric rCD2 binding to K562 is inhibited by L-fucose and following treatment of K562 with an alpha 1-6 fucosidase, whereas these treatments do not inhibit the binding of CD15 mAb. Thus, it is likely that CD2L is a carbohydrate structure closely associated with, yet distinct from, CD15, which can be sterically blocked by CD15 mAb. Functional studies revealed that CD2L is probably an important CD2 ligand in the non-MHC-restricted NK cell killing of K562 target cells, since this activity was strongly inhibited by CD15 mAb. Collectively, this study indicates that a CD15 (Lewis x)- associated carbohydrate structure(s), which has previously been shown to be a selectin ligand, also may function as an important CD2 ligand on myeloid cells.


This article has been cited by other articles:


Home page
J. Immunol.Home page
H. S. Warren, A. L. Jones, C. Freeman, J. Bettadapura, and C. R. Parish
Evidence That the Cellular Ligand for the Human NK Cell Activation Receptor NKp30 Is Not a Heparan Sulfate Glycosaminoglycan
J. Immunol., July 1, 2005; 175(1): 207 - 212.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Hiraiwa, T. Dohi, N. Kawakami-Kimura, M. Yumen, K. Ohmori, M. Maeda, and R. Kannagi
Suppression of Sialyl Lewis X Expression and E-selectin-mediated Cell Adhesion in Cultured Human Lymphoid Cells by Transfection of Antisense cDNA of an alpha 1right-arrow 3 Fucosyltransferase (Fuc-T VII)
J. Biol. Chem., December 6, 1996; 271(49): 31556 - 31561.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Nakayama, S. Nishihara, H. Iwasaki, T. Kudo, R. Okubo, M. Kaneko, M. Nakamura, M. Karube, K. Sasaki, and H. Narimatsu
CD15 Expression in Mature Granulocytes Is Determined by alpha 1,3-Fucosyltransferase IX, but in Promyelocytes and Monocytes by alpha 1,3-Fucosyltransferase IV
J. Biol. Chem., May 4, 2001; 276(19): 16100 - 16106.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.